Literature DB >> 8323331

Functional significance of dystrophin positive fibres in Duchenne muscular dystrophy.

L V Nicholson1, M A Johnson, K M Bushby, D Gardner-Medwin.   

Abstract

The age when boys lose the ability to walk independently is one of the milestones in the progression of Duchenne muscular dystrophy (DMD). We have used this as a measure of disease severity in a group of 30 patients with DMD and six patients with intermediate Duchenne/Becker dystrophy (D/BMD). Dystrophin analysis was performed on tissue sections and western blots of muscle biopsy specimens from these patients and the relationships that were found between clinical severity and abundance of dystrophin labelling are reported. All patients with intermediate D/BMD had dystrophin labelling that was detected on sections and blots. Weak dystrophin labelling was found in sections from 21/30 DMD cases and on blots in 18/30 cases. Two non-exclusive patterns of dystrophin labelling were observed on sections: very clear labelling on a small percentage of fibres (usually < 1%) or very weak labelling on a much higher proportion (about 25%). The mean age at loss of mobility among the DMD patients with no dystrophin labelling on tissue sections was 7.9 years (range 6.3-9.5) while the mean age among those with some labelling was 9.9 years (range 8.0-11.9); this is a significant difference. Quantitative estimates of dystrophin abundance were obtained from densitometric analysis of dystrophin bands on blots. In the whole group of 36 patients, a significant positive relationship was found between the abundance of dystrophin and the age at loss of independent mobility. It is concluded that even the very low concentrations of dystrophin found in DMD patients may have some functional significance.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8323331      PMCID: PMC1029331          DOI: 10.1136/adc.68.5.632

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  34 in total

1.  Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications.

Authors:  J T Den Dunnen; P M Grootscholten; E Bakker; L A Blonden; H B Ginjaar; M C Wapenaar; H M van Paassen; C van Broeckhoven; P L Pearson; G J van Ommen
Journal:  Am J Hum Genet       Date:  1989-12       Impact factor: 11.025

2.  Very mild muscular dystrophy associated with the deletion of 46% of dystrophin.

Authors:  S B England; L V Nicholson; M A Johnson; S M Forrest; D R Love; E E Zubrzycka-Gaarn; D E Bulman; J B Harris; K E Davies
Journal:  Nature       Date:  1990-01-11       Impact factor: 49.962

3.  Dystrophin: the protein product of the Duchenne muscular dystrophy locus.

Authors:  E P Hoffman; R H Brown; L M Kunkel
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

4.  Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface.

Authors:  E Bonilla; C E Samitt; A F Miranda; A P Hays; G Salviati; S DiMauro; L M Kunkel; E P Hoffman; L P Rowland
Journal:  Cell       Date:  1988-08-12       Impact factor: 41.582

5.  An autosomal transcript in skeletal muscle with homology to dystrophin.

Authors:  D R Love; D F Hill; G Dickson; N K Spurr; B C Byth; R F Marsden; F S Walsh; Y H Edwards; K E Davies
Journal:  Nature       Date:  1989-05-04       Impact factor: 49.962

6.  Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy.

Authors:  E P Hoffman; K H Fischbeck; R H Brown; M Johnson; R Medori; J D Loike; J B Harris; R Waterston; M Brooke; L Specht
Journal:  N Engl J Med       Date:  1988-05-26       Impact factor: 91.245

7.  The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle.

Authors:  E E Zubrzycka-Gaarn; D E Bulman; G Karpati; A H Burghes; B Belfall; H J Klamut; J Talbot; R S Hodges; P N Ray; R G Worton
Journal:  Nature       Date:  1988-06-02       Impact factor: 49.962

8.  Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide.

Authors:  K Arahata; S Ishiura; T Ishiguro; T Tsukahara; Y Suhara; C Eguchi; T Ishihara; I Nonaka; E Ozawa; H Sugita
Journal:  Nature       Date:  1988-06-30       Impact factor: 49.962

9.  Characterization of a 4.8kb transcript from the Duchenne muscular dystrophy locus expressed in Schwannoma cells.

Authors:  D J Blake; D R Love; J Tinsley; G E Morris; H Turley; K Gatter; G Dickson; Y H Edwards; K E Davies
Journal:  Hum Mol Genet       Date:  1992-05       Impact factor: 6.150

10.  An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus.

Authors:  A P Monaco; C J Bertelson; S Liechti-Gallati; H Moser; L M Kunkel
Journal:  Genomics       Date:  1988-01       Impact factor: 5.736

View more
  14 in total

Review 1.  What has the mdx mouse model of Duchenne muscular dystrophy contributed to our understanding of this disease?

Authors:  Jennifer Manning; Dervla O'Malley
Journal:  J Muscle Res Cell Motil       Date:  2015-02-11       Impact factor: 2.698

Review 2.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

3.  Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 2. Correlations within individual patients.

Authors:  L V Nicholson; M A Johnson; K M Bushby; D Gardner-Medwin; A Curtis; I B Ginjaar; J T den Dunnen; J L Welch; T J Butler; E Bakker
Journal:  J Med Genet       Date:  1993-09       Impact factor: 6.318

4.  Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 1. Trends across the clinical groups.

Authors:  L V Nicholson; M A Johnson; K M Bushby; D Gardner-Medwin; A Curtis; I B Ginjaar; J T den Dunnen; J L Welch; T J Butler; E Bakker
Journal:  J Med Genet       Date:  1993-09       Impact factor: 6.318

5.  Validation of a Muscle-Specific Tissue Image Analysis Tool for Quantitative Assessment of Dystrophin Staining in Frozen Muscle Biopsies.

Authors:  Famke Aeffner; Crystal Faelan; Steven A Moore; Alexander Moody; Joshua C Black; Jay S Charleston; Diane E Frank; Johannes Dworzak; J Kris Piper; Manish Ranjitkar; Kristin Wilson; Suzanne Kanaly; Daniel G Rudmann; Holger Lange; G David Young; Anthony J Milici
Journal:  Arch Pathol Lab Med       Date:  2018-08-31       Impact factor: 5.534

6.  Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin.

Authors:  L T Thanh; T M Nguyen; T R Helliwell; G E Morris
Journal:  Am J Hum Genet       Date:  1995-03       Impact factor: 11.025

7.  Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse.

Authors:  C J Mann; K Honeyman; A J Cheng; T Ly; F Lloyd; S Fletcher; J E Morgan; T A Partridge; S D Wilton
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

8.  The effects of low levels of dystrophin on mouse muscle function and pathology.

Authors:  Maaike van Putten; Margriet Hulsker; Vishna Devi Nadarajah; Sandra H van Heiningen; Ella van Huizen; Maarten van Iterson; Peter Admiraal; Tobias Messemaker; Johan T den Dunnen; Peter A C 't Hoen; Annemieke Aartsma-Rus
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

9.  Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion.

Authors:  Q L Lu; G E Morris; S D Wilton; T Ly; O V Artem'yeva; P Strong; T A Partridge
Journal:  J Cell Biol       Date:  2000-03-06       Impact factor: 10.539

10.  Targeted exon skipping to address "leaky" mutations in the dystrophin gene.

Authors:  Sue Fletcher; Carl F Adkin; Penny Meloni; Brenda Wong; Francesco Muntoni; Ryszard Kole; Clayton Fragall; Kane Greer; Russell Johnsen; Steve D Wilton
Journal:  Mol Ther Nucleic Acids       Date:  2012-10-16       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.